At what pace is the pelvic inflammatory disease (pid) treatment market growing, and what is its estimated value?
The pelvic inflammatory disease (PID) treatment market size has grown strongly in recent years. It will grow from $4.49 billion in 2024 to $4.75 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to the growing adoption of telemedicine, rising incidence of sexually transmitted infections, increasing cases of sexually transmitted infections (STIs), rising awareness of pelvic inflammatory disease, and increasing healthcare expenditure.
The pelvic inflammatory disease (PID) treatment market size is expected to see strong growth in the next few years. It will grow to $5.88 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to the increasing prevalence of sexually transmitted infections, rising awareness regarding women’s reproductive health, raising awareness about pelvic inflammatory disease, increasing reliance on telehealth services, and rising incidence of sexually transmitted infections (STIs). Major trends in the forecast period include innovative pelvic inflammatory disease treatment products, advancements in diagnostic technologies, innovations such as personalized treatment, advanced imaging techniques, and technological advancements.
Get Your Free Sample of The Global Pelvic Inflammatory Disease (PID) Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21251&type=smp
What are the top drivers to the rising demand in the pelvic inflammatory disease (pid) treatment market?
The increasing prevalence of sexually transmitted infections is expected to propel the growth of the pelvic inflammatory disease (PID) treatment market going forward. Sexually transmitted infections (STIs) are infections caused by bacteria, viruses, or parasites that are primarily spread through sexual contact, including vaginal, anal, or oral sex. The increasing prevalence of sexually transmitted infections (STIs) is due to factors such as risky sexual behaviors, unprotected sex, lack of awareness, delayed testing, and treatment. Pelvic inflammatory disease (PID) treatment is useful for managing sexually transmitted infections (STIs) as it involves the use of antibiotics to eliminate infection-causing bacteria, prevents complications such as chronic pelvic pain and infertility, and reduces the risk of recurrent infections. For instance, in October 2024, according to a report published by the UK Health Security Agency (UKHSA), a UK-based government agency, in 2023, England recorded 6,008 new human immunodeficiency virus (HIV) diagnoses, marking a 51% increase compared to the 3,975 diagnoses in 2022. Therefore, the increasing prevalence of sexually transmitted infections is driving the growth of the pelvic inflammatory disease (PID) treatment market.
How is the pelvic inflammatory disease (pid) treatment market segmented?
The pelvic inflammatory disease (PID) treatment market covered in this report is segmented –
1) By Treatment Type: Antibiotic Therapy, Surgery, Pain Management, Hormonal Therapy
2) By Route Of Administration: Oral, Intravenous, Intramuscular
3) By End User: Hospitals, Clinics, Homecare
Subsegments:
1) By Antibiotic Therapy: Broad-spectrum Antibiotics, Combination Antibiotic Therapy, Oral Antibiotics, Intravenous Antibiotics
2) By Surgery: Laparoscopy, Hysterectomy, Tubal Surgery
3) By Pain Management: Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Opioid Analgesics, Acetaminophen, Localized Pain Management
4) By Hormonal Therapy: Birth Control Pills, Hormonal Intrauterine Device (IUD), Progesterone Therapy
Order your report now for swift delivery
Who are the top competitors in the pelvic inflammatory disease (pid) treatment market?
Major companies operating in the pelvic inflammatory disease (PID) treatment market are Pfizer Inc., Bayer AG, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Mayne Pharma Group Limited, Saphnix Lifesciences, Aristo Pharmaceuticals Pvt. Ltd., Zydus Cadila Healthcare Ltd., Amagen India Life Sciences.
What significant trends should we anticipate in the pelvic inflammatory disease (pid) treatment market over the forecast period?
Major companies operating in the pelvic inflammatory disease (PID) treatment market are focusing on innovative formulations, such as probiotic supplements, to enhance treatment efficacy, restore vaginal microbiota balance, and reduce the recurrence of infections in patients with pelvic inflammatory disease (PID). A probiotic supplement is a product containing beneficial live bacteria or yeasts that help maintain or restore a healthy balance of gut and vaginal microbiota. For instance, in November 2024, Lee Health Domain, an India-based pharmaceutical company, launched V-Ferin, a probiotic supplement designed to support vaginal health. Formulated with Lactobacillus acidophilus, lactoferrin peptide, and cranberry extract, V-Ferin aims to restore the natural microbiome and prevent common vaginal infections like bacterial vaginosis and yeast infections. With around 25-30% of women affected by these conditions, which can lead to pelvic inflammatory disease if untreated, V-Ferin offers a novel solution to improve health and prevent complications.
Which regional trends are influencing the pelvic inflammatory disease (pid) treatment market, and which area dominates the industry?
North America was the largest region in the pelvic inflammatory disease (PID) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pelvic inflammatory disease (PID) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Pelvic Inflammatory Disease (PID) Treatment Market Report 2025 Offer?
The pelvic inflammatory disease (pid) treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Pelvic inflammatory disease (PID) treatment refers to the medical management of infections affecting the female reproductive organs, typically caused by sexually transmitted bacteria such as Chlamydia trachomatis and Neisseria gonorrhoeae. Treatment aims to eliminate the infection, alleviate symptoms, and prevent complications such as infertility, chronic pelvic pain, and ectopic pregnancy.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21251
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
